Short answer: yes. Anabolic–androgenic steroids (AAS) can suppress LH and FSH so strongly that sperm production falls to very low levels or stops altogether. Pregnancy may still occur during use, so AAS are not contraception. After stopping, sperm production often returns, but recovery can take several months to more than a year and is less predictable after long, high-dose or multi-compound use.
AAS-related infertility is usually a problem of sperm production rather than a permanent loss of the ability to father a child. The distinction matters: a man may have high testosterone in the bloodstream and still have very little testosterone inside the testes, where sperm are made.
How Anabolic Steroids Suppress Sperm Production
The male reproductive system is controlled by the hypothalamic–pituitary–gonadal axis, or HPG axis. The hypothalamus releases gonadotrophin-releasing hormone (GnRH) in pulses. The pituitary responds by releasing luteinising hormone (LH) and follicle-stimulating hormone (FSH).
LH acts on the Leydig cells in the testes and stimulates the production of testosterone. FSH acts mainly through Sertoli cells, which support developing sperm. Normal sperm production requires both signals, as well as a very high concentration of testosterone inside the testes.
When an external androgen is introduced, the brain detects the increased androgen signal and reduces GnRH release. LH and FSH then fall. Blood testosterone may remain high, particularly during a testosterone cycle or while using long-acting compounds, but intratesticular testosterone can fall sharply. That is why a high serum testosterone result does not show that sperm production is intact.
The result ranges from a modest reduction in sperm concentration to severe oligospermia or azoospermia. Oligospermia means a low sperm concentration; azoospermia means that no sperm are found in the ejaculate on the test performed. Motility and morphology may also worsen.
Spermatogenesis takes about 74 days, followed by further maturation and transport through the reproductive tract. A semen analysis therefore reflects hormonal conditions from roughly the previous two to three months. An early test after stopping AAS can still look poor even if the HPG axis has started to recover.
Suppression can begin within weeks, although the speed and depth vary. Dose, ester length, cycle duration, stacking, age, baseline fertility and previous exposure all matter. The general pattern is consistent: exogenous androgens suppress gonadotrophins and reduce sperm output, often to very low or undetectable levels (source).
Specific Compounds and Fertility Impact
All AAS can suppress fertility through the same basic feedback loop, but the degree of suppression depends on the total androgen exposure and how long the HPG axis remains switched down.
Testosterone replacement therapy versus supraphysiological AAS doses
Testosterone replacement therapy (TRT) is prescribed for men with confirmed hypogonadism. The aim is to restore testosterone to a physiological range, not to create bodybuilding-level concentrations. Even correctly prescribed TRT can lower LH and FSH and reduce sperm production. Some men become azoospermic while taking it.
A man who wants to preserve fertility should raise that issue before starting TRT. Depending on the diagnosis, a clinician may consider fertility-preserving treatment such as hCG-based therapy or a selective oestrogen receptor modulator rather than exogenous testosterone. The correct choice depends on the cause of low testosterone and the semen results.
Non-medical AAS use generally involves supraphysiological exposure, often with several compounds used together for 8–16 weeks or longer. The stronger and more sustained androgen signal usually produces deeper suppression than standard TRT. Stacking also makes recovery harder to predict because the last active compound may remain in the body for weeks after the final injection.
Trenbolone and other common AAS compounds
Trenbolone, nandrolone decanoate, boldenone undecylenate, oxandrolone, stanozolol and testosterone esters can all suppress LH and FSH. None should be treated as fertility-sparing. A non-aromatising compound can still suppress the HPG axis through androgen-receptor signalling.
Nandrolone and trenbolone are 19-nortestosterone derivatives with additional progestogenic activity. That may add another suppressive signal in some users, particularly when they are combined with other androgens. Oral 17-alpha-alkylated AAS add liver and lipid risks, but their fertility effect still mainly comes from suppression of the HPG axis rather than from direct toxicity to sperm.
There is no commonly used muscle-building AAS combination that reliably preserves sperm production. Lower doses may produce less suppression in some men, but a low dose is not a dependable fertility strategy.
Non-AAS compounds: clenbuterol and MK-677
Clenbuterol and MK-677 are often discussed alongside steroids, but neither is an anabolic steroid. Clenbuterol is a beta-2 adrenergic agonist. MK-677, or ibutamoren, is a growth-hormone secretagogue that acts at the ghrelin receptor.
They do not suppress LH and FSH through the same direct androgen-feedback mechanism as testosterone or nandrolone. However, that does not make them harmless or fertility-neutral. Human fertility data for MK-677 are limited, while clenbuterol can cause cardiovascular strain, palpitations, sleep disturbance and electrolyte problems. Poor sleep, illness, weight changes and cardiovascular stress can all affect reproductive health indirectly.
Can You Get Pregnant While Your Partner Is on Steroids?
Yes. AAS reduce fertility, but they do not reliably remove it. Some men become azoospermic; others continue to produce a small number of motile sperm. Without a semen analysis, there is no reliable way to know which situation applies.
A man can have normal libido, normal erections and a high testosterone level while producing no sperm. Another man on a similar-looking cycle may have severe oligospermia but still release enough sperm for conception. Sperm concentration, progressive motility and morphology all affect the chance of pregnancy, as do the female partner’s age and reproductive health.
For that reason, AAS should never be used as contraception. Couples who do not want a pregnancy should use an established contraceptive method. Couples trying to conceive should arrange a semen analysis rather than assuming that a cycle has made conception impossible.
For an initial assessment, provide two semen samples collected 2–7 days after ejaculation, ideally at least two to three weeks apart if the first result is abnormal. The World Health Organization lower reference values are approximately 16 million sperm per millilitre, 39 million sperm per ejaculate, 30% progressive motility and 4% normal morphology. These are reference limits, not a sharp boundary between fertility and infertility: pregnancy can occur below them, and a result above them does not guarantee conception.
Steroid Use and Birth Defects
There are two separate questions: whether paternal AAS use makes conception harder, and whether it increases the risk of birth defects after conception.
The first is well established. AAS commonly reduce sperm concentration and motility, which lowers the chance of natural conception. The evidence for the second question is much less definite. Good human data directly linking a father’s AAS use with congenital abnormalities are limited. Animal findings and concerns about sperm DNA damage are biologically relevant, but they do not establish a specific birth-defect risk in humans.
Sperm DNA integrity can also be affected by age, obesity, smoking, heavy alcohol use, fever, inflammation, sleep loss and some medicines. AAS may contribute to oxidative stress in some users, but a plausible mechanism is not the same as a proven clinical outcome.
A useful distinction is that reduced sperm production and damaged sperm are not the same finding. The fertility-suppressing effect of AAS is well documented, whereas the risk of teratogenic effects from paternal AAS exposure remains uncertain (source).
Recovery: Can Sperm Production Return After Stopping Steroids?
Often, yes. Recovery is common after stopping AAS, but it is not immediate and it is not guaranteed. The first step is to stop exogenous androgens. Continuing testosterone, nandrolone, trenbolone or another suppressive compound while attempting recovery usually keeps LH and FSH down.
After the last dose, recovery time depends on the compound. Shorter-acting preparations may clear over days, whereas long-acting testosterone and nandrolone esters can continue to suppress the axis for several weeks. Sperm production then needs another roughly three months to reflect the new hormonal environment. Many men need three to six months; some need 12 months or longer.
A practical fertility-recovery work-up
Before starting medication, obtain two semen analyses and morning blood tests for total testosterone, SHBG, calculated or free testosterone, LH, FSH, prolactin, estradiol, full blood count, liver enzymes and lipid profile. Repeat testosterone, LH and FSH about 4–6 weeks after stopping a short-acting cycle, or later when a long ester has cleared. Repeat semen analysis at approximately 12 weeks, then every 8–12 weeks if it remains abnormal.
Persistently undetectable LH and FSH with low or low-normal testosterone indicates ongoing central suppression. A total testosterone below about 12 nmol/L, particularly with symptoms, deserves clinical assessment, but there is no single testosterone value that diagnoses fertility. A semen result showing azoospermia should be confirmed with a second sample; if it persists, a fertility specialist may arrange centrifuged pellet examination and further investigation.
Medical treatment used to restore sperm production
There is no universal post-cycle therapy protocol for fertility. In reproductive medicine, treatment is selected according to the semen result and hormone pattern rather than started automatically.
- hCG: a commonly used clinical starting range is 1,500–3,000 IU injected subcutaneously two or three times weekly for 8–12 weeks. It acts like LH and restores intratesticular testosterone. Testosterone and estradiol are checked during treatment; a persistently high estradiol level, breast tenderness, marked fluid retention or worsening mood requires review rather than automatic addition of an aromatase inhibitor.
- FSH or hMG: if hCG has restored intratesticular testosterone but sperm remain absent or severely reduced, clinicians commonly add recombinant FSH or hMG at roughly 75–150 IU two or three times weekly. Treatment often continues for at least three months because sperm development is slow, and it may take six months or longer.
- Clomifene: clinicians may use 25 mg daily or 25 mg on alternate days to stimulate endogenous LH and FSH. Review is usually based on symptoms and blood tests after 4–6 weeks. Visual symptoms, severe mood changes or significant headaches require stopping the drug and urgent review.
- Tamoxifen: 20 mg daily is another off-label option sometimes used to stimulate gonadotrophin release, although it is not automatically superior to clomifene. Leg swelling, chest pain, breathlessness or visual symptoms require urgent medical attention.
Clomifene and tamoxifen should not be combined casually, and an aromatase inhibitor should not be added solely because estradiol is detectable. Estradiol is necessary for male bone, sexual and metabolic health; treatment is considered when the level is clearly elevated in context and symptoms or laboratory findings support it. hCG, FSH, SERMs and aromatase inhibitors require prescription, monitoring and adjustment.
When recovery is incomplete
Longer exposure, higher cumulative doses, repeated cycles, older age and pre-existing testicular or pituitary problems make recovery less predictable. If sperm are still absent after 6–12 months of appropriately monitored treatment, the specialist may investigate genetic causes, varicocele, obstruction, prolactin disorders and primary testicular failure.
If adequate sperm cannot be restored in the ejaculate, surgical sperm retrieval with IVF/ICSI may still be possible in selected cases. That decision depends on whether sperm can be found in the testes and on the female partner’s fertility assessment.
Female Fertility and Anabolic Steroids
AAS can disrupt fertility in women as well as men. Testosterone-derived compounds may produce irregular periods, anovulatory cycles and reduced ovarian function by disturbing the hypothalamic–pituitary–ovarian axis.
Androgenic effects can include acne, increased facial and body hair, male-pattern hair loss, clitoral enlargement and voice deepening. Some changes improve after stopping, but voice deepening and some genital changes may be permanent.
Women concerned about menstrual changes, fertility or virilisation need a sex-specific assessment. The appropriate tests and recovery expectations differ from those used in men.
This article is for information only and is not a substitute for individual diagnosis or treatment. Fertility response varies considerably between individuals. The medication ranges above describe protocols used in clinical practice and are not a personal prescription. Anyone using or stopping AAS, or planning a pregnancy, should arrange appropriate blood tests and semen analysis with a qualified clinician. This is particularly important with chronic conditions, prescription medicines, abnormal results or persistent symptoms. No specific outcome can be promised.